These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8438618)

  • 41. [Specificity of the protective action of a ribosomal Shigella vaccine and the absence of activity in the ribosomes from R mutants].
    Levenson VI; Rukhadze EZ; Belkin ZP; Essaulova ME
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Oct; (10):55-9. PubMed ID: 2464261
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outpatient studies of the safety and immunogenicity of an auxotrophic Escherichia coli K-12-Shigella flexneri 2a hybrid vaccine candidate, EcSf2a-2.
    Taylor DN; Phillip DF; Zapor M; Trofa A; Van de Verg L; Hartman A; Bendiuk N; Newland JW; Formal SB; Sadoff JC
    Vaccine; 1994 May; 12(6):565-8. PubMed ID: 8036831
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenic value of live, inactivated and cell-free dysentery vaccines.
    Meitert T; Sulea IT; Gogulescu L; Baron E; Tempea C; Istrati G
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):103-7. PubMed ID: 4613127
    [No Abstract]   [Full Text] [Related]  

  • 44. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis.
    Sansonetti PJ; Arondel J
    Vaccine; 1989 Oct; 7(5):443-50. PubMed ID: 2683460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
    Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM
    Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Field trials with an oral cell-free vaccine made from Shigella flexneri].
    Sergeev VV; Kreĭnin LS; Elkina SI; Kaverina KG; Levina LA
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Oct; (10):54-9. PubMed ID: 2692352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent Shigella sonnei vaccine in an institution with endemic disease.
    Levine MM; Gangarosa EJ; Barrow WB; Weiss CF
    Am J Epidemiol; 1976 Jul; 104(1):88-92. PubMed ID: 779465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of an auxotrophic oral live Shigella flexneri vaccine.
    Lindberg AA; Kärnell A; Stocker BA; Katakura S; Sweiha H; Reinholt FP
    Vaccine; 1988 Apr; 6(2):146-50. PubMed ID: 2838986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Self-experiments with ingestion of various bacteria.
    Rédey B
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):45-62. PubMed ID: 4216252
    [No Abstract]   [Full Text] [Related]  

  • 50. [The antigenic and immunogenic properties of the bivalent strain Shigella flexneri-Shigella sonnei 1 No. 200].
    Bondarenko VM; Nikolaeva AI; Marakusha BI; Belova TS
    Zh Mikrobiol Epidemiol Immunobiol; 1995; (6):47-8. PubMed ID: 8553752
    [No Abstract]   [Full Text] [Related]  

  • 51. Shigellosis: the current status of vaccine development.
    Kweon MN
    Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.
    Rahman KM; Arifeen SE; Zaman K; Rahman M; Raqib R; Yunus M; Begum N; Islam MS; Sohel BM; Rahman M; Venkatesan M; Hale TL; Isenbarger DW; Sansonetti PJ; Black RE; Baqui AH
    Vaccine; 2011 Feb; 29(6):1347-54. PubMed ID: 21040694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates.
    Ranallo RT; Fonseka S; Boren TL; Bedford LA; Kaminski RW; Thakkar S; Venkatesan MM
    Vaccine; 2012 Jul; 30(34):5159-71. PubMed ID: 22658966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.
    Kotloff KL; Pasetti MF; Barry EM; Nataro JP; Wasserman SS; Sztein MB; Picking WD; Levine MM
    J Infect Dis; 2004 Nov; 190(10):1745-54. PubMed ID: 15499528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of a polyvalent protein-polysaccharide dysentery oral vaccine.
    Zhang HM; Li YP; Song LH; Yu XL; Liu NH; Kong XE; Li L; Zhai YL
    Chin Med J (Engl); 1987 May; 100(5):425-8. PubMed ID: 3115716
    [No Abstract]   [Full Text] [Related]  

  • 56. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.
    Katz DE; Coster TS; Wolf MK; Trespalacios FC; Cohen D; Robins G; Hartman AB; Venkatesan MM; Taylor DN; Hale TL
    Infect Immun; 2004 Feb; 72(2):923-30. PubMed ID: 14742537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Mechanism of immunogenesis during vaccination with streptomycin-dependent mutants of salmonellae and shigellae. V. Dynamics of antibody-producing cells in monkey lymphoid tissue].
    Krasnoproshina LI; Elkina SI; Sergeev VV; Kavtaradze KN
    Zh Mikrobiol Epidemiol Immunobiol; 1973 Aug; 50(8):71-6. PubMed ID: 4206261
    [No Abstract]   [Full Text] [Related]  

  • 58. Safety and antigenicity of typhoid-Shigella sonnei vaccine (strain 5076-1C).
    Tramont EC; Chung R; Berman S; Keren D; Kapfer C; Formal SB
    J Infect Dis; 1984 Feb; 149(2):133-6. PubMed ID: 6366077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
    Farzam N; Ramon-Saraf R; Banet-Levi Y; Lerner-Geva L; Ashkenazi S; Kubler-Kielb J; Vinogradov E; Robbins JB; Schneerson R
    Vaccine; 2017 Sep; 35(37):4990-4996. PubMed ID: 28797729
    [TBL] [Abstract][Full Text] [Related]  

  • 60. T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans.
    Toapanta FR; Bernal PJ; Kotloff KL; Levine MM; Sztein MB
    J Transl Med; 2018 Mar; 16(1):61. PubMed ID: 29534721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.